Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AAPG Ascentage Pharma Group International	$41.13 -0.7%	$40.83	$16.50 ▼ $48.45	$3.85B	N/A	9,530 shs	2,554 shs
ACAD ACADIA Pharmaceuticals	$26.23 -1.3%	$23.28	$13.40 ▼ $26.65	$4.48B	0.7	2.02 million shs	2.21 million shs
KRYS Krystal Biotech	$150.76 +2.1%	$145.52	$122.80 ▼ $207.84	$4.27B	0.7	415,013 shs	252,307 shs
RCUS Arcus Biosciences	$10.62 +0.5%	$9.39	$6.50 ▼ $18.98	$1.12B	0.89	763,071 shs	633,062 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AAPG Ascentage Pharma Group International	-3.14%	-12.29%	+5.42%	+63.31%	+4,139,999,900.00%
ACAD ACADIA Pharmaceuticals	+3.30%	+6.54%	+17.46%	+19.20%	+68.70%
KRYS Krystal Biotech	+0.52%	+1.22%	-3.45%	+17.54%	-25.52%
RCUS Arcus Biosciences	+1.83%	+4.86%	+7.36%	+11.26%	-39.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	3.4135 of 5 stars	2.3	2.0	0.0	0.0	3.4	4.2	2.5
KRYS Krystal Biotech	4.7179 of 5 stars	3.5	1.0	0.0	4.7	2.6	3.3	2.5
RCUS Arcus Biosciences	2.4012 of 5 stars	3.4	3.0	0.0	0.0	3.0	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AAPG Ascentage Pharma Group International	3.00	Buy	N/A	N/A
ACAD ACADIA Pharmaceuticals	2.61	Moderate Buy	$28.88	10.08% Upside
KRYS Krystal Biotech	3.00	Buy	$210.38	39.54% Upside
RCUS Arcus Biosciences	2.75	Moderate Buy	$21.14	99.18% Upside

Current Analyst Ratings Breakdown

Latest RCUS, AAPG, KRYS, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$219.00 ➝ $216.00
8/22/2025	KRYS Krystal Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$240.00
8/8/2025	ACAD ACADIA Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$32.00 ➝ $36.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
8/7/2025	ACAD ACADIA Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sell ➝ Sell	$15.00 ➝ $17.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$39.00 ➝ $40.00
8/7/2025	ACAD ACADIA Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$23.00 ➝ $24.00
8/7/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$37.00 ➝ $38.00
8/7/2025	RCUS Arcus Biosciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$26.00 ➝ $25.00
8/5/2025	KRYS Krystal Biotech	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$176.00 ➝ $166.00
8/5/2025	KRYS Krystal Biotech	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$219.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AAPG Ascentage Pharma Group International	$134.35M	28.46	N/A	N/A	$1.01 per share	40.72
ACAD ACADIA Pharmaceuticals	$957.80M	4.62	$0.70 per share	37.69	$4.87 per share	5.39
KRYS Krystal Biotech	$290.52M	15.02	$4.73 per share	31.84	$35.96 per share	4.19
RCUS Arcus Biosciences	$262M	4.31	N/A	N/A	$5.16 per share	2.06

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AAPG Ascentage Pharma Group International	-$55.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	$226.45M	$1.33	19.72	34.51	6.76	21.80%	14.69%	9.41%	11/5/2025 (Estimated)
KRYS Krystal Biotech	$89.16M	$4.92	30.64	14.96	N/A	40.85%	15.21%	13.81%	11/3/2025 (Estimated)
RCUS Arcus Biosciences	-$283M	-$3.17	N/A	N/A	N/A	-109.56%	-55.96%	-25.73%	11/5/2025 (Estimated)

Latest RCUS, AAPG, KRYS, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	$0.16	+$0.02	$0.16	$263.07 million	$264.57 million
8/6/2025	Q2 2025	RCUS Arcus Biosciences	-$1.14	-$1.1053	+$0.0347	N/A	$32.86 million	$160.00 million
8/4/2025	Q2 2025	KRYS Krystal Biotech	$1.08	$1.29	+$0.21	$1.29	$95.42 million	$96.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AAPG Ascentage Pharma Group International	N/A	N/A	N/A	N/A	N/A
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KRYS Krystal Biotech	N/A	N/A	N/A	N/A	N/A
RCUS Arcus Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AAPG Ascentage Pharma Group International	1.31	1.54	1.53
ACAD ACADIA Pharmaceuticals	N/A	2.91	2.83
KRYS Krystal Biotech	N/A	9.68	9.33
RCUS Arcus Biosciences	0.18	4.50	4.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AAPG Ascentage Pharma Group International	N/A
ACAD ACADIA Pharmaceuticals	96.71%
KRYS Krystal Biotech	86.29%
RCUS Arcus Biosciences	92.89%

Insider Ownership

Company	Insider Ownership
AAPG Ascentage Pharma Group International	N/A
ACAD ACADIA Pharmaceuticals	26.50%
KRYS Krystal Biotech	13.70%
RCUS Arcus Biosciences	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AAPG Ascentage Pharma Group International	600	92.96 million	N/A	N/A
ACAD ACADIA Pharmaceuticals	510	168.71 million	124.00 million	Optionable
KRYS Krystal Biotech	210	28.94 million	24.98 million	Optionable
RCUS Arcus Biosciences	500	106.43 million	96.21 million	Optionable

RCUS, AAPG, KRYS, and ACAD Headlines

Recent News About These Companies

Swiss National Bank Boosts Stake in Arcus Biosciences, Inc. $RCUS

August 28 at 3:26 AM | marketbeat.com

Vanguard Group Inc. Has $52.50 Million Position in Arcus Biosciences, Inc. $RCUS

August 28 at 3:11 AM | marketbeat.com

Arcus Biosciences, Inc. $RCUS Stock Holdings Lifted by Algert Global LLC

August 24, 2025 | marketbeat.com

Arcus Biosciences, Inc. $RCUS Shares Purchased by Public Sector Pension Investment Board

August 24, 2025 | marketbeat.com

Arcus Biosciences to Participate in Three Upcoming Investor Conferences

August 22, 2025 | theglobeandmail.com

Gilead Sciences Inc. Raises Position in Arcus Biosciences, Inc. (NYSE:RCUS)

August 19, 2025 | marketbeat.com

Jim Cramer on Arcus Biosciences: “Let This Be Your Speculation”

August 16, 2025 | finance.yahoo.com

Cramer's Lightning Round: Uranium Energy is a buy

August 14, 2025 | msn.com

Arcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from Brokerages

August 12, 2025 | marketbeat.com

Cantor Fitzgerald Issues Positive Forecast for RCUS Earnings

August 11, 2025 | marketbeat.com

Q3 EPS Forecast for Arcus Biosciences Reduced by Analyst

August 11, 2025 | marketbeat.com

Leerink Partnrs Has Negative Estimate for RCUS Q3 Earnings

August 11, 2025 | marketbeat.com

Wedbush Forecasts Lower Earnings for Arcus Biosciences

August 11, 2025 | marketbeat.com

Arcus Biosciences: A Risky Buy Ahead Of Pivotal, Catalyst-Rich 12 Months

August 10, 2025 | seekingalpha.com

Arcus Biosciences (NYSE:RCUS) Stock Rating Upgraded by Wall Street Zen

August 10, 2025 | marketbeat.com

Wedbush Decreases Earnings Estimates for Arcus Biosciences

August 9, 2025 | marketbeat.com

Arcus Biosciences (NYSE:RCUS) Price Target Lowered to $25.00 at Wells Fargo & Company

August 8, 2025 | marketbeat.com

Gilead hands back one Arcus cancer candidate from $725M deal

August 7, 2025 | fiercebiotech.comF

Arcus (RCUS) Q2 Revenue Jumps 310%

August 6, 2025 | fool.com

Arcus Biosciences, Inc. (RCUS) Reports Break-Even Earnings for Q2

August 6, 2025 | zacks.com

Arcus Biosciences Reports Second-Quarter 2025 Financial Results and Provides a Pipeline Update

August 6, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RCUS, AAPG, KRYS, and ACAD Company Descriptions

Ascentage Pharma Group International NASDAQ:AAPG

$41.13 -0.27 (-0.65%)

As of 02:15 PM Eastern

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. It engages in the development of novel therapies for cancers, hepatitis B virus, or HBV, and age-related diseases. The company was founded by Da Jun Yang, Wang Shao Meng and Ming Guo in May 2009 and is headquartered in Suzhou, China.

ACADIA Pharmaceuticals NASDAQ:ACAD

$26.23 -0.34 (-1.28%)

Closing price 04:00 PM Eastern

Extended Trading

$26.23 0.00 (0.00%)

As of 07:40 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Krystal Biotech NASDAQ:KRYS

$150.76 +3.12 (+2.11%)

Closing price 04:00 PM Eastern

Extended Trading

$150.85 +0.09 (+0.06%)

As of 05:36 PM Eastern

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Arcus Biosciences NYSE:RCUS

$10.62 +0.06 (+0.52%)

Closing price 03:59 PM Eastern

Extended Trading

$10.61 -0.01 (-0.05%)

As of 06:27 PM Eastern

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time